New study aims to unravel nerve damage in rare blood cancer

NCT ID NCT07160270

Recruiting now Knowledge-focused Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at why many people with Waldenström's macroglobulinemia, a rare blood cancer, develop nerve damage that can cause pain, numbness, and trouble moving. Researchers will examine 90 patients to find out how common this nerve damage is and what causes it. The goal is to help doctors diagnose the problem faster so they can start treatment early and prevent lasting harm.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to faster diagnosis of nerve damage in Waldenström's macroglobulinemia patients, helping doctors start treatment earlier to prevent permanent disability.
What could go wrong: This is an observational study, not a treatment trial. It may not directly improve outcomes, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL NEUROPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral nervous system disorder peripheral neuropathy Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL NEUROPATHIES WALDENSTROM MACROGLOBULINAEMIA

Contacts and locations

Locations

Copenhagen Neuromuscular Center, Rigshospitalet Blegdamsvej.
RECRUITING

København Ø, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.